BioNTech (NASDAQ:BNTX) CEO Sells 46,000 Shares of Stock

Key Points

• BioNTech CEO Ugur Sahin sold 46,000 shares at an average price of $100.72, generating $4.63 million. The Rule 10b5-1 transaction reduced his direct holdings by 10.08% to 410,209 shares.
• Sahin has conducted a series of stock sales since September 8, selling more than 300,000 shares in total over the reported transactions.
• BioNTech shares rose 2.9% to $100.87, while the company recently reported weaker-than-expected quarterly results. Analysts nevertheless maintain a “Moderate Buy” consensus rating with an average price target of $126.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 46,000 shares of the company's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00. Following the completion of the sale, the chief executive officer directly owned 410,209 shares of the company's stock, valued at $41,316,250.48. This represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.

BioNTech Trading Up 2.9%

Shares of BNTX stock traded up $2.87 during trading hours on Tuesday, hitting $100.87. The company had a trading volume of 1,050,346 shares, compared to its average volume of 1,100,679. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The stock has a market capitalization of $25.51 billion, a PE ratio of -12.88 and a beta of 1.29. The company's fifty day moving average is $97.54 and its 200 day moving average is $94.82. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. During the same quarter last year, the business posted ($1.60) EPS. The firm's revenue for the quarter was down 59.5% on a year-over-year basis. Research analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the topic of several analyst reports. UBS Group reiterated a "buy" rating on shares of BioNTech in a research note on Wednesday, September 16th. Canaccord Genuity Group lowered their price target on BioNTech from $142.00 to $136.00 and set a "buy" rating for the company in a report on Monday, August 31st. Morgan Stanley cut their price objective on shares of BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a report on Wednesday, July 8th. Citigroup cut their price target on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a research note on Wednesday, August 5th. Finally, BMO Capital Markets downgraded shares of BioNTech from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $126.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BNTX. Larson Financial Group LLC lifted its position in BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company's stock worth $26,000 after acquiring an additional 127 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of BioNTech during the 2nd quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd raised its stake in shares of BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company's stock worth $53,000 after buying an additional 506 shares in the last quarter. Vestcor Inc acquired a new stake in shares of BioNTech in the 4th quarter valued at approximately $153,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in shares of BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company's stock valued at $177,000 after buying an additional 1,423 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.